PBLS PBLS
Company Profile ↓Company Overview
PBLS (PBLS) is a publicly traded company listed on with a market capitalization of $4.12B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.22.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +10.44% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | +14.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)58.69 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 40.24M | 47.45M |
| Operating Income | -40.24M | -47.45M |
| EBITDA | -37.27M | -44.42M |
| Interest Expense | 399.00K | 292.00K |
| Pretax Income | -38.33M | -45.32M |
| Tax Provision | - | - |
| Net Income | -38.33M | -45.32M |
| Diluted EPS | -0.60 | -0.56 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 126.12M | 152.08M |
| Operating Income | -126.12M | -152.08M |
| EBITDA | -114.33M | -141.87M |
| Interest Expense | 1.49M | 1.52M |
| Pretax Income | -117.91M | -145.89M |
| Tax Provision | - | - |
| Net Income | -117.91M | -145.89M |
| Diluted EPS | -2.01 | -1.81 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 149.25M | 80.82M |
| Current Assets | 92.21M | 29.36M |
| Cash & Equivalents | 47.28M | 27.71M |
| Inventory | - | - |
| Receivables | 360.00K | 0 |
| Total Liabilities | 92.81M | 97.34M |
| Current Liabilities | 32.41M | 56.79M |
| Long Term Debt | 12.79M | - |
| Total Debt | 66.20M | 58.70M |
| Total Equity | 56.44M | -16.52M |
| Shares Outstanding | 118.15M | 118.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -103.61M | -123.71M |
| Investing Cash Flow | 30.24M | 39.76M |
| Financing Cash Flow | 78.07M | 64.38M |
| Capital Expenditure | -879.00K | -306.00K |
| Free Cash Flow | -104.49M | -124.02M |
| Net Change in Cash | 4.70M | -19.57M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | -208.9% | 882.9% |
| ROCE % | -107.9% | -632.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PBLS
Parabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day Decline
Why Parabilis Medicines Stock Is On Investors’ Radar Parabilis Medicines (PBLS) has recently drawn fresh attention after a sharp single day move, with the stock closing at $27.26 and down around 10% over that session. For investors tracking…
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet …
How to Play PBLS Stock After the Parabilis IPO
Parabilis stock soared on its Nasdaq debut, but a deeper dive suggests PBLS shares could extend gains further through the remainder of 2026.
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet …
PBLS — Frequently Asked Questions
What is the current share price of PBLS?
As of 2026-08-05 17:25 PDT, PBLS trades at $34.90 on NASDAQ/NYSE. Its 52-week range is $25.01 to $35.90.
What is the market capitalisation of PBLS?
PBLS has a market capitalisation of $4.12B on NASDAQ/NYSE.
What is the P/E ratio of PBLS?
PBLS trades at a trailing price-to-earnings (P/E) ratio of -19.28. Its price-to-book (P/B) ratio is -249.46.
Is PBLS a good stock to buy?
This page provides a data-driven analysis of PBLS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.